Chiasma — Corporate Update (July 2019)
15 slides from Chiasma's corporate update, Jul 23, 2019
Slide 1: Chiasma OPTIMAL Top-line Results
Chiasma OPTIMAL Top-line Results JULY 23, 2019 NASDAQ: CHMA Exhibit 99.2
Slide 2: Forward-Looking Statements
Forward-Looking Statements These slides and the accompanying presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” a
Slide 3: Acromegaly: A Rare and Debilitating Hormonal Disorder
Acromegaly: A Rare and Debilitating Hormonal Disorder Caused by excessive secretion of growth hormone (GH) stemming from a benign pituitary tumor ~69,000* patients worldwide Features include enlarged hands, feet and internal organs, and altered facial features Significant comorbidities lead to prema
Slide 4: Orphan, Addressable U.S. Acromegaly Market Opportunity
Orphan, Addressable U.S. Acromegaly Market Opportunity 1.Endocrinology market studies. 2.Company estimates Sizing the Acromegaly Market Addressing the Market Cured through surgery Not treated with SSAs Chronically treated with SSA injections ~14,0001 ~8,0002 ~2,0002 # of U.S. Patients Diagnosed Acro
Slide 5: Current Injection Therapies Carry Significant Treatment Burdens
Current Injection Therapies Carry Significant Treatment Burdens* Emotional Impact 36% feel loss of independence due to chronic injections Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammation (7%) Lost Work Days 16% regularly miss work for injections
Slide 6: CHIASMA OPTIMAL Trial Met Its Endpoints
CHIASMA OPTIMAL TRIAL* MET ITS ENDPOINTS Study met its primary endpoint and all secondary endpoints in acromegaly patients Positive top-line data brings us a step closer to advancing Mycapssa to registration with the FDA NDA resubmission planned by year end 2019 with an anticipated mid-2020 PDUFA da
Slide 7: CHIASMA OPTIMAL – Study Design
CHIASMA OPTIMAL – Study Design Open Label Extension Double-blind placebo-controlled (DPC) (36 weeks) Eligibility criteria: Average IGF-1 ≤ 1.0 ´ ULN Confirm active disease (IGF-1 ≥ 1.3 x ULN post last surgery) Pre-defined withdrawal criteria (both arms) IGF-1 ≥1.3 x ULN for 2 consecutive visits on t
Slide 8: Subject Disposition and Demographics
Subject Disposition and Demographics 56 patients, 28 per group (octreotide capsules or placebo) 38% from the U.S. All patients completed trial No missing primary endpoint data Baseline characteristics well balanced between the groups
Slide 9: 58% Maintained IGF-1 Response on Octreotide Capsules vs. 19% on Placebo
58% Maintained IGF-1 Response on Octreotide Capsules vs. 19% on Placebo (p = 0.008) Primary Endpoint: Proportion of patients who maintain biochemical response at end of 36 weeks p = 0.008
Slide 10: 78% Maintained GH Response on Octreotide Capsules vs. 30% on Placebo
78% Maintained GH Response on Octreotide Capsules vs. 30% on Placebo (p = 0.001) 1st Secondary Endpoint: Proportion of patients who maintain GH response at week 36 (of GH responders at screening) p = 0.001
Slide 11: Median Time to Loss of Response Not Reached for Octreotide Capsules
Median Time to Loss of Response Not Reached (>36 Weeks) for Patients on Octreotide Capsules (p < 0.001) Median time to loss of response Octreotide Capsules Placebo p Value 2nd Secondary Endpoint: IGF-1 >1.0×ULN Not reached 16 weeks < 0.001 3rd Secondary Endpoint: IGF-1 ≥1.3×ULN Not reached 16 weeks
Slide 12: 25% on Octreotide Capsules Began Rescue vs. 68% on Placebo
25% of Patients on Octreotide Capsules Began Rescue with SSA Injections vs. 68% on Placebo (p = 0.003) Confidential 4th Secondary Endpoint: Proportion of patients who began rescue treatment p = 0.003
Slide 13: 90% Who Completed Trial Opted to Continue into Open Label Extension
90% Who Completed Trial with Octreotide Capsules Opted to Continue into the Open Label Extension 90% continued to OLE Patients completed 36-weeks on Mycapssa Patients elected to continue on Mycapssa
Slide 14: Octreotide Capsules Appeared Safe and Well Tolerated
Octreotide Capsules Appeared Safe and Well Tolerated Octreotide Capsules Placebo Subjects with: n % n % At least one TEAE 28 100% 27 96.4 Treatment-Related TEAE 18 64.3 15 53.6 SAEs 2 7.1 1 3.6 Treatment-Related SAEs 0 0.0 0 0.0 Severe TEAEs 3 10.7 7 25.0 TEAE Leading to Study Drug Discontinuation 2
Slide 15: CHMA Investment Highlights
CHMA Investment Highlights Rare and Orphan Disease Focus Registration-Ready Lead Asset Lead asset targeting adults with acromegaly Octreotide capsules (Mycapssa®), if approved, positioned to become the first oral somatostatin analog in an injectable-only market Positive top-line safety and efficacy